The China question, FDA leadership shakeups, and other biotech news from The Readout global health FDA HHS Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home Newsletter The Readout AstraZeneca picks up FDA approval for hypertension drug The China question, FDA leadership shakeups, and other biotech news from…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today we’re bringing you a special report: a fascinating look at how China’s growing role in global drug development is deeply dividing the U.S. biotech industry, with executives openly debating whether reliance on Chinese partners is a competitive necessity or a national security risk.
Meanwhile, the FDA’s leadership shakeup has widened, with both CBER and CDER getting new acting directors, among other changes.
Continue to STAT+ to read the full story…
US Pharma Marketing